Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations

• المؤلفون الرئيسيون: Melinda J. Gooderham (مؤلف), Marjolein de Bruin-Weller (مؤلف), Stephan Weidinger (مؤلف), Michael J. Cork (مؤلف), Lawrence F. Eichenfield (مؤلف), Eric L. Simpson (مؤلف), Athanasios Tsianakas (مؤلف), Urs Kerkmann (مؤلف), Claire Feeney (مؤلف), William Romero (مؤلف)
• التنسيق: كتاب
• منشور في: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Abstract Abrocitinib, an oral, once-daily, Janus kinase (JAK) 1-selective inhibitor, is approved for the treatment of adults and adolescents with moderate-to-severe atopic dermatitis (AD). Abrocitinib has shown rapid and sustained efficacy in phase 3 trials and a consistent, manageable safety profil...